Vancouver, British Columbia, March 9, 2022 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) Is pleased to announce that its wholly owned subsidiary, TFChem, has been awarded funds to develop advanced chemical processes that can improve the production of active ingredients.
The project is funded in partnership with the French government and includes the University of Rouen in Normandy, the Rouen School of Engineering INSA, CNRS (French National Scientific Research Center, one of the world’s leading research institutes) and “Flow”. Develop “Chemistry”, an advanced technology for multi-step synthesis of compounds.
Flow chemistry enables continuous flow production of organic molecules rather than batch type production. This technology offers several advantages in the process development of Sirona compounds and active substances by reducing manufacturing costs, preventing the formation of secondary products and improving the safety of certain chemical reactions. ..
The French government will co-sponsor and hire postdoctoral students on the project, granting them free use of university facilities and access to the dedicated equipment needed to develop the process. Students will share time between TFChem’s laboratory in Val-de-Reuille and the Institute for Organic Chemistry (IRCOF) in Rouen. The contract period is one year.
Sirona Biochem Corp.about
Sirona Biochem is a cosmetic ingredients and drug discovery company with unique platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. The new compound is patented for maximum profit potential.
Sirona compounds are licensed to leading companies around the world in exchange for license fees, milestone fees and ongoing royalty payments. Sirona’s institute, TFChem, is located in France and has received several French National Science Awards and grants from the European Union and the Government of France. For more information, please visit www.sironabiochem.com.
For more information on this press release, please contact:
Phone number: 1.450.332.6939
Neither the TSX Venture Exchange nor its regulatory service provider (the term is defined in the TSX Venture Exchange Policy) is responsible for the validity or accuracy of this release.
Sirona Biochem warns that any non-explanatory statement of historical facts contained in this press release may be a forward-looking statement. Forward-looking statements are only forecasts based on current expectations and involve known and unknown risks and uncertainties. Unless otherwise stated, please be careful not to place undue reliance on these forward-looking statements that are mentioned only as of the date of publication of the relevant information. Actual results, performance, or outcomes may differ materially from those expressed or implied in Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business. .. This includes, but is not limited to, statements about clinical progress and timing. Clinical trials; difficulties or delays in development, testing, regulatory approval, product manufacturing and marketing. Unexpected adverse side effects or inadequate therapeutic effects of a product that may delay or hinder the development or commercialization of the product. The scope and effectiveness of the patent protection of the product. Competition with other pharmaceutical or biotechnology companies. And the ability to raise additional funding to support its operation. Sirona Biochem undertakes no obligation to update any forward-looking statement, except as required by law.
CBJ News Maker
Sirona Biochem’s subsidiary, TFChem, awarded funding in partnership with the French government, Canadian Business Journal
Source link Sirona Biochem’s subsidiary, TFChem, awarded funding in partnership with the French government, Canadian Business Journal